Open to Debate: Con

Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Con

Teele Kuusk, Axel Bex

*Department of Urology, Royal London Hospital, Barts Health NHS Trust, London, UK; Specialist Centre for Kidney Cancer, The Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, London, UK; Department of Urology, Antoni van Leeuwenhoek Hospital-The Netherlands Cancer Institute, Amsterdam, The Netherlands

Currently, up to half of patients presenting with treatment-naive synchronous metastatic renal cell carcinoma (mRCC) are being treated with systemic therapy when the primary tumour is in place [1]. This paradigm change followed evidence from two randomised controlled trials investigating the role (CARMENA [2]) and sequence of cytoreductive nephrectomy (CN; SURTIME [3]) in the era of VEGF targeted therapy. However, as evidence matures from the pivotal immune checkpoint inhibitor (ICI) combination trials demonstrating complete response rates at metastatic sites of up to 16% and median overall survival (OS) of 4 yr, an increasing number of patients with primary mRCC on ICI therapy are being offered deferred CN following a disease response [4]. Whether partial nephrectomy (PN) is of benefit in this patient population is debatable and we argue against this approach for several reasons.

First, it needs to be acknowledged that only few undisputed indications remain for CN. Indications for upfront CN traditionally include patients with good performance status and low-volume metastatic disease that can either be focally treated or observed with the aim of delaying systemic therapy and related adverse events. These represent only 25% of patients with primary mRCC [1]. A recent unplanned post hoc analysis of CARMENA data suggests that indications for upfront CN may be extended to patients with International Metastatic RCC Database Consortium (IMDC) intermediate prognosis on the basis of only one risk factor [5]. An even smaller percentage require upfront CN because of symptoms.

On the basis of the CARMENA data, guidelines currently recommend treating the majority of patients with intermediate IMDC risk with systemic therapy and to consider deferred CN, including the poor risk group if response to therapy is good [5,6]. Despite the assumption that the overall indication for deferred CN may therefore increase, overall response rates to systemic therapy range from 46% to 60%, with complete responses occurring in only one in every ten patients [6]. Real-world data for patients treated with nivolumab and ipilimumab with the primary tumour in place revealed that only 13% were offered deferred CN [7]. Thus, cytoreductive surgery for the primary tumour as a procedure, whether upfront or deferred, has become a rare intervention for which to select candidates for PN.

An additional argument against PN in the metastatic setting is the complexity of primary tumours. In metastatic disease, primary tumours are 9 cm in diameter on average [2,3] and although downsizing can be expected on ICI combination therapy [7,8], a reduction in primary tumour diameter of ≥30% occurs in only one-third of patients [8]. According to real-world data for patients in the intermediate IMDC group treated with dual ICI and the primary tumour in place, the baseline median primary tumour size was 14 cm, which decreased by a median of only 12.9% [7]. Therefore, the majority of tumours remain too complex for PN (Table 1). For the upfront CN setting, it has been reported that the prevalence of primary tumours of ≤4 cm is only 6.9%. Although these patients tended to have fewer metastatic sites, these were mainly located in bones and
the central nervous system, which are associated with unfavourable prognosis [9]. According to these data, OS for patients with smaller tumours suitable for PN was poor, with 2-yr and 5-yr survival rates of 65% and 28%, respectively.

This leads to the potentially most significant argument against PN in the metastatic setting. The generally accepted benefit of PN in the nonmetastatic setting is long-term preservation of renal function, which is associated with better OS [6]. However, despite impressive improvements in median OS and some individuals potentially being cured with ICI therapies, life expectancy remains limited for the majority of patients with mRCC. This in turn would not justify PN for kidney function preservation in these very few patients who would be eligible for nephron-sparing surgery, unless imperative.

In the retrospective series of patients treated with the primary tumour in place, some dramatic responses have been described following ICI combination therapy, with primary tumour downsizing of >70% to <4 cm in diameter [7,8]. We acknowledge that it is tempting to consider PN in these individual cases, but it should be noted that the evidence for this approach is poor. The role of cytoreductive treatment of the primary tumour following response to ICI combination therapy is a dynamic and evolving field. Two randomised controlled trials (PROBE [NCT04510597] and NORDICSUN [NCT03977571]) are accruing patients to randomised controlled trials (PROBE [NCT04510597] and NORDICSUN [NCT03977571]) are accruing patients to continue investigating this approach. Nevertheless, until evidence of OS improvement becomes available, it may be more prudent to consider less invasive management options such as ablation or stereotactic radiotherapy for tumours after dramatic shrinkage. Although equally unproven options in the metastatic setting, these avoid the morbidity of surgery and may be promising because of their abscopal effect. The CYTOSHrink trial (NCT04090710) is investigating stereotactic radiotherapy of the primary tumour following ICI combination therapy and results are eagerly awaited [10].

Finally, systemic therapy for mRCC is not nephrotoxic and therefore nephron-sparing surgery is rarely needed. A recent retrospective study demonstrated that reduced kidney function is not a predisposing risk for cancer-specific mortality in patients with nonmetastatic T1–T3a RCC [11]. This suggests that reduced renal function does not impact on management of recurrences from kidney cancer.

In summary, we argue that imperative situations aside, PN is not indicated for patients with synchronous mRCC.

The decreasing indication for cytoreductive removal of the primary tumour, the complexity of the kidney mass at baseline, and limited life expectancy caution against performing nephron-sparing surgery in the metastatic setting. In a situation in which even deferred CN has a low evidence base, PN should not be performed just because it is technically feasible. However, the concept of PN may be revisited if ongoing trials demonstrate long-term OS following deferred CN in patients responding to ICI combination therapy.

Conflicts of interest: The authors have nothing to disclose.

References

[1] Liu WK, Lam JM, Butters T, et al. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach. World J Urol 2020;38:3199–205. https://doi.org/10.1007/s00345-020-03107-0.
[2] Mejean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379:417–27.
[3] Box A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 2019;5:164–70.
[4] Mori K, Qubal F, Yanagisawa T, et al. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: a systematic review and meta-analysis. Int Immunopharmacol 2022;108:108720.
[5] Mejean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol 2021;80:417–24.
[6] Ljungberg B, Albiger L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.006.
[7] Meerveld-Eggink A, Graafland N, Wilgenhof S, et al. Primary renal tumour response in patients treated with nivolumab and ipilimumab for metastatic renal cell carcinoma: real-world data assessment. Eur Urol Open Sci 2022;35:54–8.
[8] Albiger L, Tannir NM, Burotto M, et al. First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial. Eur Urol 2022;81:266–71.
[9] DiNatale RG, Xie W, Becerra MF, et al. The association between small primary tumor size and prognosis in metastatic renal cell carcinoma: insights from two independent cohorts of patients who underwent cytoreductive nephrectomy. Eur Urol Oncol 2020;3:47–56.
[10] Lalani AK, Swanimath A, Pond GR, et al. Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRRINK). J Clin Oncol 2020;38:6 Suppl, abstract 826. https://doi.org/10.1200/JCO.2020.38.6_suppl.TPS761.

---

**Table 1 – Response of the primary tumour**

| Author                  | Systemic therapy                  | Primary tumour in place | Median tumour size (cm) | Median primary tumour reduction (%) |
|-------------------------|-----------------------------------|-------------------------|-------------------------|------------------------------------|
| Meerveld-Eggink [7]     | Nivolumab/ipilimumab              | 69                      | 10.14                   | 3.4                                | 33.3                               |
| Albige [8]              | Nivolumab/ipilimumab              | 49                      | 7.9                     | 2.4                                | >30                                |
| Courrier [12] (NIVOREN) | Second- or third-line nivolumab   | 67                      | 8                       | 2.4                                | 30                                 |
| Albige [13]             | Avelumab/axitinib                 | 55                      | 34.5                    | NA                                 | NA                                 |

PR = partial response; dCN = deferred cytoreductive nephrectomy; NA = not applicable.
[11] Palacios DA, Zabor EC, Munoz-Lopez C, et al. Does reduced renal function predispose to cancer-specific mortality from renal cell carcinoma? Eur Urol 2021;79:774–80.

[12] Courcier J, Dalban C, Laguerre B, et al. Primary renal tumour response in patients treated with nivolumab for metastatic renal cell carcinoma: results from the GETUG-AFU 26 NIVOREN trial. Eur Urol 2021;80:325–9.

[13] Albiges L, Rini BI, Haanen JBAG, et al. Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC). Ann Oncol 2019;30:v359–60.